Earnings Report | 2026-04-16 | Quality Score: 95/100
Earnings Highlights
EPS Actual
$-0.04
EPS Estimate
$-0.0422
Revenue Actual
$1271789000.0
Revenue Estimate
***
US stock product cycle analysis and innovation pipeline tracking to understand future growth drivers. Our product research helps you identify companies with upcoming catalysts that could drive stock price appreciation.
Tempus AI Inc. (TEM) has released its latest the previous quarter earnings results, marking the most recently available financial data for the precision medicine AI firm as of this month. The company reported quarterly revenue of approximately $1.27 billion, with an adjusted earnings per share (EPS) of -$0.04 for the quarter. The results cover the final quarter of the company’s prior fiscal year, and reflect both ongoing revenue growth from its core product lines and continued investments in res
Executive Summary
Tempus AI Inc. (TEM) has released its latest the previous quarter earnings results, marking the most recently available financial data for the precision medicine AI firm as of this month. The company reported quarterly revenue of approximately $1.27 billion, with an adjusted earnings per share (EPS) of -$0.04 for the quarter. The results cover the final quarter of the company’s prior fiscal year, and reflect both ongoing revenue growth from its core product lines and continued investments in res
Management Commentary
During the official earnings call, Tempus AI leadership focused on three core highlights from the quarter: expanded adoption of its AI-powered clinical decision support tools across U.S. oncology care networks, a series of new multi-year partnership agreements with top biopharmaceutical clients for clinical trial patient recruitment and real-world evidence generation, and progress in the development of its next-generation generative AI models designed to analyze genomic sequencing data for rare disease diagnosis. Management noted that the quarterly operating expense levels were aligned with previously disclosed investment plans, with a majority of new spending allocated to scaling R&D teams and expanding the company’s de-identified real-world patient data repository, which is a core input for its AI models. Leadership also emphasized that recurring revenue from enterprise biopharma clients grew at a faster rate than one-off service revenue during the quarter, a trend they view as a positive indicator of long-term customer retention.
TEM (Tempus AI Inc.) tops EPS estimates and posts 83 percent year over year revenue growth, shares fall 3.53 percent today.Investor psychology plays a pivotal role in market outcomes. Herd behavior, overconfidence, and loss aversion often drive price swings that deviate from fundamental values. Recognizing these behavioral patterns allows experienced traders to capitalize on mispricings while maintaining a disciplined approach.Cross-asset correlation analysis often reveals hidden dependencies between markets. For example, fluctuations in oil prices can have a direct impact on energy equities, while currency shifts influence multinational corporate earnings. Professionals leverage these relationships to enhance portfolio resilience and exploit arbitrage opportunities.TEM (Tempus AI Inc.) tops EPS estimates and posts 83 percent year over year revenue growth, shares fall 3.53 percent today.Quantitative models are powerful tools, yet human oversight remains essential. Algorithms can process vast datasets efficiently, but interpreting anomalies and adjusting for unforeseen events requires professional judgment. Combining automated analytics with expert evaluation ensures more reliable outcomes.
Forward Guidance
Tempus AI did not issue specific numerical forward guidance alongside the the previous quarter earnings release, but outlined key strategic priorities for upcoming operational periods. These priorities include scaling deployment of its latest clinical AI tools to additional hospital systems, expanding commercial operations in select international markets, and continuing to invest in AI model training to improve the accuracy of its diagnostic and treatment recommendation tools. Analyst consensus estimates suggest that the company’s revenue growth may remain steady in upcoming periods, driven by broader industry adoption of AI in healthcare and life sciences workflows. However, market analysts also note that ongoing R&D and market expansion investments could potentially keep operating margins under pressure in the near term, as the company prioritizes market share capture over near-term profitability.
TEM (Tempus AI Inc.) tops EPS estimates and posts 83 percent year over year revenue growth, shares fall 3.53 percent today.Monitoring market liquidity is critical for understanding price stability and transaction costs. Thinly traded assets can exhibit exaggerated volatility, making timing and order placement particularly important. Professional investors assess liquidity alongside volume trends to optimize execution strategies.Incorporating sentiment analysis complements traditional technical indicators. Social media trends, news sentiment, and forum discussions provide additional layers of insight into market psychology. When combined with real-time pricing data, these indicators can highlight emerging trends before they manifest in broader markets.TEM (Tempus AI Inc.) tops EPS estimates and posts 83 percent year over year revenue growth, shares fall 3.53 percent today.Macro trends, such as shifts in interest rates, inflation, and fiscal policy, have profound effects on asset allocation. Professionals emphasize continuous monitoring of these variables to anticipate sector rotations and adjust strategies proactively rather than reactively.
Market Reaction
Following the release of the the previous quarter earnings results, TEM traded with near-average volume in subsequent sessions, reflecting mixed investor sentiment around the results. Sell-side analyst notes published after the call indicate that the reported revenue figure was roughly in line with consensus market expectations, while the adjusted EPS figure was slightly ahead of prior analyst estimates. Some market participants have focused positively on the company’s growing recurring revenue share and expanding partnership pipeline, while others have raised questions about the expected timeline for the company to reach positive adjusted operating margins. The broader healthcare AI subsector has seen heightened volatility in recent weeks, which may also be contributing to TEM’s post-earnings price action, as investors re-evaluate growth expectations for AI-enabled enterprise software firms across sectors.
Disclaimer: This analysis is for informational purposes only and does not constitute investment advice.
TEM (Tempus AI Inc.) tops EPS estimates and posts 83 percent year over year revenue growth, shares fall 3.53 percent today.Scenario planning is a key component of professional investment strategies. By modeling potential market outcomes under varying economic conditions, investors can prepare contingency plans that safeguard capital and optimize risk-adjusted returns. This approach reduces exposure to unforeseen market shocks.Correlating futures data with spot market activity provides early signals for potential price movements. Futures markets often incorporate forward-looking expectations, offering actionable insights for equities, commodities, and indices. Experts monitor these signals closely to identify profitable entry points.TEM (Tempus AI Inc.) tops EPS estimates and posts 83 percent year over year revenue growth, shares fall 3.53 percent today.Diversifying information sources enhances decision-making accuracy. Professional investors integrate quantitative metrics, macroeconomic reports, sector analyses, and sentiment indicators to develop a comprehensive understanding of market conditions. This multi-source approach reduces reliance on a single perspective.